Browse Articles
Discover research articles across all indexed journals
Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.
155 Background: Primary results from the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study of rucaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi) in patients with chemotherapy-naive mCRPC and BRCA1/2 (BRCA) vs the control arm of physician’s choice of DTX or ARPI (abiraterone acetate [ABI] or enzalutamide [ENZ]) demonstrated that rucaparib significantly improved radiographic progression-free survival (rPFS, primary efficacy endpoint) vs physician’s choice. Here, we report final OS and safety results from TRITON3. Methods: Patients with disease progression after 1 prior second-generation ARPI in any setting were randomized 2:1 to rucaparib 600 mg BID or physician’s choice of DTX, ABI, or ENZ (control). OS was a key secondary endpoint tested initially in the BRCA subgroup, followed by the intent-to-treat (ITT) population in an ordered step-down multiple-comparisons procedure. Crossover from placebo to rucaparib was allowed after radiographic progression was confirmed by independent radiology review. Results: As of March 1, 2024 (final analysis data cutoff),patients with BRCA (N = 302) and ATM (N = 103) alterations were randomized (ITT, N = 405). After an overall median follow-up of 44.0 months, median OS in the BRCA subgroup in the rucaparib arm was 23.2 months vs 21.2 months for the physician’s choice control arm (HR, 0.91 [95% CI, 0.68–1.20]; P = 0.5044; Table). Hierarchical testing did not continue due to lack of statistical significance. No OS benefit was observed in the ITT population or ATM subgroup (Table). Median duration of treatment in rucaparib and physician’s choice arms was 8.3 and 5.1 months, respectively. The most frequent any-grade treatment emergent adverse event (TEAE) in the rucaparib (n = 270) and physician’s choice (n = 130) arms was asthenia/fatigue (61.5% and 63.1%, respectively). The most frequent grade ≥3 TEAE was anemia (23.7%) with rucaparib, and asthenia/fatigue (9.2%) with physician’s choice. Of the 135 patients in the physician’s choice arm, 77 patients had radiographic progression and 70 crossed over to rucaparib. Conclusions: Rucaparib remains the only PARPi to show improved rPFS vs a DTX-containing control arm and has a similar OS even when most patients cross over to rucaparib. Safety was consistent with prior reports. These data support rucaparib as a treatment option for patients with BRCA-mutated mCRPC. Clinical trial information: NCT02975934 . Median OS at final analysis. Group Rucaparib, n Physician's choice, n Rucaparib, months Physician's choice, months HR (95% CI) a BRCA 201 101 23.2 21.2 0.91 (0.68–1.20) ITT 270 135 22.8 21.7 0.99 (0.78–1.26) ATM 69 34 18.4 22.1 1.21 (0.77–1.90) a Calculated by stratified Cox proportional hazard model.
Androgen receptor alterations and survival in veterans who develop metastatic castrate resistant prostate cancer.
269 Background: Despite the increasing use of comprehensive genetic tumor profiling, molecular data has limited influence in determining treatment. However, with new therapies that target the androgen receptor in metastatic castration-resistant prostate cancer (mCRPC), molecular alterations in the androgen receptor signaling pathway have increasing importance. We sought to examine the association between androgen receptor (AR) alterations and overall survival in patients with metastatic hormone sensitive prostate cancer (mHSPC). Methods: In this retrospective study, we identified patients diagnosed with de novo mHSPC and treated with androgen deprivation therapy (ADT) between 2017 to 2021 within the Veterans Health Affairs. AR gene alterations were identified using National Precision Oncology testing from samples collected within 90 days before or after the mCRPC diagnosis date. Overall survival (OS) and time to mCRPC were compared between patients with and without AR alterations in patients whose samples were collected during mCRPC. Normally distributed variables were analyzed via t-test, nonnormal continuous variables via Kruskal-Wallis, and categorical variables via chi-square. Results: We identified 2431 patients with de novo metastatic prostate cancer who had somatic tumor testing (551 mCRPC samples and 1922 mHSPC samples). In samples collected in mCRPC, 40.8% (225) had AR alterations compared to 3.3% (65) in mHSPC patients (p<0.001). Of the mCRPC samples, 68.1% (375) were obtained via liquid biopsy, 74.2% (167) had a single AR alteration, and 25.8% (58) had two or more AR alterations (p<0.001). The most frequent AR alterations identified were amplification (n=135), T878A (n=48), L702H (n=40), H875Y (n=27), exon 4-8 rearrangement or deletions (n=23), W742L (n=11), and W742C (n=11). In patients with mCRPC samples, time to mCRPC was 31.3 months in patients with AR alterations compared to 34.7 months without AR alterations, HR 1.08 (95% CI: 0.91-1.28) (p=0.4). In mCRPC samples with AR alterations, the median overall survival was 56.8 months compared to 76.7 months in patients without AR alterations, HR 1.40 (95% CI: 1.15-1.70) (p<0.001). Conclusions: There are significantly more AR alterations in tissue samples collected from de novo metastatic prostate cancer patients who have progressed to mCRPC compared to samples collected at mHSPC. In patients tested during mCRPC, presence of AR alteration was associated with shorter overall survival compared to those without AR alterations. Genomic analysis of tumors at the time of disease progression may be an informative prognostic indicator and facilitate selection of therapy. No AR alteration (n=326) AR alteration present (n=225) HR (95% CI) p-value Time to mCRPC (months) 34.7 31.3 1.08 (0.91-1.28) 0.4 Overall survival (months) 76.6 56.8 1.40 (1.15-1.70) <0.001
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.
471 Background: Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC) representing up to 15% of RCC. First line (1L) phase II trials have evaluated immunotherapy (IO) in combination with IO or tyrosine kinase inhibitors (TKI) in nccRCC, but these cohorts are heterogeneous, with few comparative results. Therefore, the specific value of IO therapy for pRCC remains unquantified. Methods: We conducted an analysis based on prospectively collected data from the Canadian Kidney Cancer information system (CKCis) database. The objective was to evaluate efficacy of 1L systemic therapy of metastatic pRCC with either IO based or VEGFR-TKI. Baseline characteristics, treatment outcome and safety were collected. Primary endpoint was time-to-treatment failure (TTF). Secondary endpoints included overall survival (OS), objective response rate (ORR), adverse events requiring a change in dose/schedule (TRAEs). TTF, OS and ORR were adjusted (adj) for IMDC risk groups. Results: Between 01/2011 to 01/2024,206 pRCC pts were treated: 70 on IO single agent or in combination IO-IO/IO-TKI and 136 with TKI monotherapy. The median follow-up was 20.6 months (mo) (range: 1.6-146.1). There were no significant differences in baseline characteristics between 2 groups, described in table. The median TTF with IO was 9.8 mo (95%CI: 4.5, 15.9) versus (vs) 5.7 mo with TKI (95%CI: 4.6, 8.1) (adj HR: 0.61 [0.42-0.89] p=0.01). The median OS was 36.9 mo with IO (95%CI: 26.5, not reached (NR)) vs 21.6 mo with TKI (95%CI: 18, 27.9) (adj HR: 0.51 [0.3-0.85], p=0.009). Among the 170 evaluable pts, ORR was 37% (95% CI: 24.2-49.9) with IO and 21.5% (95% CI: 14.1-29) with TKI (adj OR: 2.4 [1.0-5.6] p=0.04). The TKI-IO subgroup had better TTF and OS compared to TKI therapy, with 16.9 mo (95%CI: 5.5-22.6) (adj HR: 0.46 [0.26-0.82] p=0.009), and NR (95%CI: 18.9-NR) (adj HR: 0.24 [0.08-0.78] p=0.02) respectively. 28% of pts discontinued treatment. TRAEs of grade 3-5 were noted in 27% in IO group and in 73% in TKI group. Conclusions: This study presents comparative data on 1L treatment metastatic pRCC. It shows an improved TTF and OS in the IO group, particularly in TKI-IO treated pts. Our findings underline the need for further clinical trials evaluating 1L IO in pts with metastatic pRCC. Baseline characteristics. Overall cohortn = 206 IO treatmentn = 70 (34%) TKI treatmentn = 136 (66%) Median age (range) 67 (30-89) 69 67 Sex Male 162 (79%) 51 (73%) 111 (82%) IMDC score Favorable Intermediate Poor Unknown 31 (20%)93 (60%)30 (19.5%)52 15 (29%)30 (58%)7 (13%)18 16 (16%)63 (62%)23 (22%)34 Prior Nephrectomy 164 (80%) 56 (80%) 108 (79%) Sarcomatoid component 12 (8%) 5 (7%) 7 (5%) Therapy Nivolumab + ipilimumab Pembrolizumab + axitinib Pembrolizumab + lenvatinib Pembrolizumab Nivolumab Sunitinib Pazopanib Cabozantinib Crizotinib Savolitinib m-Tor inhibitors 27 (13%)23 (11%)7 (3.5%)11 (5%)2 (1%) 88 (43%)20 (10%)8 (4%)3 (1.5%)7 (3.5%)9 (4.5%)
Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)
Characterizing immunogenicity of <i>MYC-</i> amplified, metastatic prostate cancer as reflected by the recovery rates of adaptive immune receptor recombinations from RNAseq files.
241 Background: In prostate cancer, identifying biomarkers to predict patients who are at higher risk for metastatic disease remains a key question. The interaction of oncogenes such as MYC with the adaptive immune system may be a potential marker for worse progression; for example, MYC -amplified neuroblastoma has been shown to be immunologically cold both in vitro and with respect to the amount of adaptive immune receptor (IR) recombinations recovered from genomics files. Thus, we performed a correlative study identifying the relationship between MYC amplification and detection of adaptive IR recombinations in genomics files in prostate cancer. Methods: We utilized datasets for this study: The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD, n = 475), Count Me In-Metastatic Prostate Cancer (CMI-MPC, n= 63) and West Coast Dream Team – Metastatic Castration Resistant Prostate Cancer (WCDT-MCRPC, n = 76). Copy number variation (CNV) assessments were done for the cases in these studies, identifying oncogene amplification as those with high ratios of exome, tumor to blood sequencing read counts for a given gene. We also mined productive IR recombination sequencing reads from RNAseq files, with associated V and J-IDs, as described in Chobrutskiy et al. 2020, which yielded reads for TRA , TRB , TRD , TRG , IGH , IGK , and IGL . Then, MYC-amplified cases and MYC-deficient cases were compared with a two-proportion test for progression-free survival and with a t-test for the counts of IR receptors. Results: We first determined that, for TCGA-PRAD dataset, cases representing the top 20 MYC read tumor to blood count ratios, in comparison to all other cases, represented a poorer progression free survival (p = 0.01) at the 70-month timepoint. We also noted that average MYC CN in both metastatic prostate cancer datasets (CMI-MPC and WCDT-MCRPC) was higher than in the TCGA-PRAD dataset, which represented primary tumor samples (p < 0.001 for both analyses). Further, for the WCDT-MCRPC dataset, we found that MYC -amplified cases were associated with significantly reduced IGH , IGK , and IGL recombination reads in RNA-seq files (p = 0.005, 0.01, 0.004 respectively). For the WCDT-MCPRC dataset, we found that MYC -amplified cases were associated with reduced TRA and TRB recombination reads in WGS files (p = 0.008 and 0.017 respectively). Conclusions: This report further evidences the negative effects of MYC amplification with regard to immune evasion and being a key driver of prostate cancer metastasis. This report thus supports risk stratification by MYC-amplification, as well as noting that patients with MYC-amplification may benefit more from immune-boosting therapies. In particular, this report identifies immunoglobulins and by proxy, B-cells, as a major deficiency in those with MYC-amplified prostate cancer.
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
659 Background: In the phase 3 NIAGARA study of patients (pts) with muscle-invasive bladder cancer (MIBC), perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) and overall survival (OS) compared with NAC alone, with a manageable safety profile and no detriment to the ability to undergo radical cystectomy (RC). We report additional outcomes and an exploratory analysis from NIAGARA. Methods: NIAGARA enrolled cisplatin-eligible pts with MIBC (cT2-T4aN0/1M0) planned for RC. Pts were randomized 1:1 to receive either neoadjuvant D (1500 mg IV Q3W) and NAC (cisplatin + gemcitabine IV Q3W) for 4 cycles followed by RC, then adjuvant D monotherapy (1500 mg IV Q4W) for 8 cycles (D arm), or NAC followed by RC alone (comparator arm). Dual primary endpoints were EFS and pCR. OS was a key secondary endpoint. Metastasis-free survival and disease-specific survival were secondary endpoints. An exploratory post hoc analysis of EFS and OS in pts with pCR vs without pCR (non-pCR) was also performed. Efficacy analyses were conducted in the intent-to-treat population (data cutoff [DCO] April 2024). Results: A total of 1063 pts were randomized (533 D arm; 530 comparator arm). Pts in the D arm had a 33% reduction in risk of developing distant metastases or death (hazard ratio [HR] 0.67; 95% CI 0.54–0.83; nominal P <0.001) and 31% reduction in risk of death from bladder cancer (HR 0.69; 95% CI 0.52–0.91; nominal P =0.008) vs pts in the comparator arm. More pts in the D vs comparator arm had pCR at RC (37% vs 28%); pts who achieved pCR had better EFS and OS vs non-pCR. Pts in the D arm derived greater EFS and OS benefit vs the comparator arm in both pCR (EFS HR 0.58; OS HR 0.72) and non-pCR (EFS HR 0.77; OS HR 0.84) groups (Table). Overall, immune-mediated AEs (imAEs) were reported in 111/530 (21%) pts in the D arm (grade 3/4 3%) and 16/526 (3%) in the comparator arm (grade 3/4 0.2%). At DCO, all imAEs were resolved for 45/111 (41%) pts (D arm) and 7/16 (44%) pts (comparator arm). The most common imAEs were hypothyroid events (10% D arm; 1% comparator arm) and hyperthyroid events (3% D arm; 0.8% comparator arm). Conclusions: Perioperative D with NAC reduced the risk of developing metastases and death from bladder cancer, and exploratory post hoc analyses showed that D improved EFS and OS in both pCR and non-pCR groups. imAEs were consistent with the known profile of D and mostly low grade. These data further support perioperative D as a potential new standard treatment for pts with MIBC. Funding: AstraZeneca. Clinical trial information: NCT03732677 . pCR Non-pCR D N=199 Comparator N=146 HR (95% CI) D N=334 Comparator N=384 HR (95% CI) 24-month EFS rate (95% CI), % 92 (87–95) 86 (79–91) 0.58 (0.33–1.00) 53 (48–59) 50 (44–55) 0.77 (0.63–0.95) 24-month OS rate (95% CI), % 96 (92–98) 91 (85–95) 0.72 (0.37–1.43) 74 (69–79) 69 (64–73) 0.84 (0.66–1.07)
Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.
503 Background: LDTs, including surgical resection, radiation treatment and ablation/embolization, can be employed to achieve a disease-free state in indolent oligometastatic RCC irrespective of subtype. However, the efficacy of LDTs in chRCC, a rare subtype, has not been investigated. We utilized a multi-institutional chRCC dataset to examine LDT use patterns and associated duration of disease control. Methods: Clinical and treatment characteristics of patients with chRCC and metachronous metastases were retrospectively collected from four institutions. Patients with LDT as the first metastasis-directed intervention comprised the LDT cohort, while those who started systemic treatment (ST) upfront were included in the ST cohort. Wilcoxon rank-sum test and Fisher’s exact test were used for comparison of continuous and categorical variables, respectively. Systemic treatment-free survival (STFS, duration between upfront LDT and subsequent ST initiation or last follow-up) was calculated by Kaplan-Meier method. Results: 104 patients were included: 48 in the LDT cohort and 56 in the ST cohort.Median age and gender were comparable across the two cohorts. Compared to patients who initiated ST, patients who underwent LDT had a longer interval between nephrectomy and metastatic disease diagnosis (49 months [IQR 30. 93] vs 14 months [IQR 4, 47], p <0.001), were less likely to have tumors with sarcomatoid dedifferentiation (6% vs 34%, p <0.001), had an earlier disease stage at initial diagnosis (Stage I 33% vs 9%, Stage II 12% vs 31%, Stage III 55% vs 56%, p=0.004) and were more likely to have a single metastatic site (79% vs 52%, p=0.002). In the LDT cohort, 39 (81%) patients underwent surgery, 7 (14%) radiation and 4 (8%) ablation/embolization. The majority (30 [61%]) underwent a single LDT, while serial LDTs were utilized in the remainder: 12 (25%) with 2 LDTs and 6 (12%) with ≥3. The most frequently treated sites with LDT were the lymph node (27%), soft tissue (23%) and liver (15%). The median interval between first and second LDT was 20 months (IQR 7, 32), and between the second and third LDT was 7 months (IQR 1, 10). At a median follow-up of 60 months, median STFS was 32 months (95% CI, 20, 46). One- and two-year STFS rates were 84% and 62%. Conclusions: This is thefirst study to systematically evaluate LDT use and outcomes in chRCC managed at centers of expertise. LDTs were more frequently utilized in patients with single-organ metastasis, longer time between nephrectomy and recurrence, and absence of sarcomatoid dedifferentiation. In a carefully selected population, LDTs can lead to clinically meaningful treatment-free interval in chRCC.
Phase I trial of hypofractionated radiotherapy and pembrolizumab in the treatment of muscle invasive/metastatic bladder cancer: Results of the PLUMMB trial.
756 Background: The objective of the PLUMMB trial (NCT02560636) was to assess the safety, tolerability and efficacy of the addition of the anti-PD1 antibody Pembrolizumab with hypofractionated weekly bladder radiotherapy (RT) in patients with advanced/metastatic bladder cancer. We present the final results, subject to database lock and statistical QC. Methods: The trial aimed to recruit 28 patients planned for RT to the bladder with a dose escalation phase (modified 3+3) of 7 dose cohorts to determine the primary endpoint maximum tolerated dose (MTD), and a dose expansion phase to answer the secondary endpoints: acute toxicity (up to 6 weeks post RT); late toxicity (until 28 days post Pembrolizumab (CTCAE - Common Terminology Criteria for Adverse Events) or 2 years post RT (RTOG - Radiation Therapy Oncology Group)); progression free survival (PFS); overall survival (OS); and local control of bladder cancer. Exploratory endpoint was control of bladder related symptoms. Results: Between Sep 2016 and Nov 2023, 28 patients were recruited: median age 75 (IQR 69-85), white, majority male (79%), ever-smokers (75%). Three (11%) had locally advanced (T2a-T2b N0 M0) and 25 (89%) had nodal/metastatic bladder cancer (T1b-T4 N0-N3 M0-M1b). Two patients did not receive any Pembrolizumab or RT so were excluded from endpoint analyses. Three patients remain on Pembrolizumab (all ≥6 months post RT). Five patients experienced dose limiting toxicity (DLT) (see table) and the MTD was confirmed at 24Gy in 6 fractions (f) and Pembrolizumab 200mg, which was the expansion cohort. The rates of worst acute toxicity in patients who had ≥2 doses of Pembrolizumab, ≥4f of RT and had a toxicity assessment 6 weeks post RT were: 4/20 (20%) grade 1; 12 (60%) grade 2; and 4 (20%) grade 3. For late toxicity in patients who had ≥1 dose of Pembrolizumab, 1f of RT and survived to 6 weeks post RT: 15/24 (63%) reported grade 2+ and 8 (33%) grade 3+ using CTCAE; and 5 (21%) reported grade 2 using RTOG not within 3 months of disease progression (0 grade 3+). For patients who had ≥1 dose of Pembrolizumab and 1f of RT: 13/26 (50%) had a response as per RECIST 1.1 (7 CR, 6 PR, 6 SD, 6 PD - best response). PFS and OS was 31% (95%CI: 15-49) and 62% (95%CI: 40-77) at 1 year, and 16% (95%CI: 5-34) and 33% (95%CI: 15-51) at 2 years, respectively. Finally, 12/24 (50%) patients were free of grade 2+ bladder symptoms at 3 months post RT, and 8 (33%) at 6 months. Conclusions: DLT is seen when combining 6Gy fractions of radiotherapy and Pembrolizumab 100-200mg, but 24Gy in 6f radiotherapy with Pembrolizumab is safe and effective in the treatment of advanced bladder cancer with 50% of patients having a favourable response. Clinical trial information: NCT02560636 . Dose Cohort Radiotherapy Pembrolizumab Number registered (%) Number with DLT A-1 36Gy in 6f 100 6 (21) 3 A-2 36Gy in 6f 200 B-1a 24Gy in 6f 100 1 (4) B-1b 24Gy in 6f 200 12 (43) B-2a 24Gy in 4f 100 4 (14) B-2b 24Gy in 4f 200 5 (18) 2 B-3a 30Gy in 5f 200
Molecular-dipole oriented universal growth of conjugated polymers into semiconducting single-crystal thin films
Unveiling the drivers of active participation in social media discourse
The effect of circadian rhythm–based medication timing adjustments on the efficacy and safety of novel hormonal therapy.
TPS277 Background: Neoadjuvant hormonal therapy (NHT) serves as the primary treatment approach for metastatic hormone-sensitive prostate cancer (mHSPC) by either inhibiting androgen synthesis or blocking androgen receptor binding, thereby suppressing tumor growth. Despite its effectiveness, patients with mHSPC inevitably develop resistance to NHT over time, advancing to metastatic castration-resistant prostate cancer (mCRPC), which is associated with a poor prognosis. Androgen synthesis and secretion exhibit a prominent circadian rhythm, with accelerated synthesis in the early morning, peaking around 8:00 AM, followed by a decline to nadir by approximately 8:00 PM. Administrating NHT agents during nighttime may enhance therapeutic efficacy by preemptively inhibiting androgen synthesis and receptor binding before the peak secretion period. Consequently, we have designed a prospective study to evaluate and compare the efficacy and safety of daytime versus nighttime administration of NHT agents in patients with mHSPC. Methods: This prospective, open-label, phase II study will enroll 70 patients with mHSPC. Key eligibility criteria include histologically or pathologically confirmed prostate cancer, classified as mHSPC, without prior NHT or chemotherapy. Patients currently receiving other systemic antitumor therapies, those who have undergone organ transplantation within the past 3 months, or been diagnosed with autoimmune disease will be excluded. Eligible patients will be randomized in a 1:1 ratio to receive NHT agents either between 7:00 and 9:00 AM or between 10:00 and 12:00 PM. Treatment is continued until disease progression. The primary objective is to evaluate the effect of nighttime administration of NHT agents by assessing PSA response rate (PSA-RR), defined as the proportion of patients achieving > 90% reduction in PSA from baseline after 3 months of NHT. Secondary endpoints include circulating tumor cell (CTC) clearance rate, clinical benefit rate, objective response rate (ORR), duration of response (DoR), time to objective response, radiographic progression-free survival (rPFS), overall survival (OS), and treatment-emergent adverse events (TEAEs). Differences in response rates between the 2 groups will be analyzed using the Chi-square test. Survival endpoints will be estimated using the Kaplan-Meier method, with between-group comparisons conducted by the log-rank test. Currently, 14 of a planned total of 70 participants have been enrolled. Clinical trial information: NCT06505278 .
Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: A prospective single-arm phase II clinical trial.
530 Background: Partial nephrectomy is the standard treatment for early-stage renal cell carcinoma; however, in some patients, although the tumor is early-stage, the surgical difficulty may preclude its implementation. This study aims to evaluate the efficacy and safety of Cadonilimab combined with Lenvatinib in neoadjuvant therapy for renal cell carcinoma with indications for partial nephrectomy but high surgical risk. Methods: This is a single-center, single-arm Phase II clinical trial. Eligible patients included those with biopsy-confirmed clear cell renal carcinoma who had indications for partial nephrectomy but were at high surgical risk (criteria: 1. tumors measuring 4-7 cm located at the renal hilum or endophytic ≥75%; 2. tumors larger than 7 cm). Patients received Lenvatinib at a dosage of 8 mg or 12 mg QD combined with Cadonilimab at 6 mg/kg every two weeks for 3-6 cycles, for a total treatment duration of 6-12 weeks. Cadonilimab is a first-in-class bispecific antibody targeting both PD-1 and CTLA-4. All patients are scheduled to undergo partial nephrectomy after neoadjuvant therapy. The primary endpoint was the objective response rate (ORR) based on RECIST 1.1 criteria. Secondary endpoints included the renal preservation success rate, safety, and incidence of perioperative complications. Results: A total of 27 patients were enrolled in the study. Sixteen patients completed 6 cycles of Cadonilimab treatment, 6 patients completed 3 cycles, and 5 patients did not complete the pre-set treatment cycles. One patient underwent surgery after experiencing a grade 4 adverse event (diabetic ketoacidosis) following the second cycle of Cadonilimab; four patients discontinued treatment for subjective reasons and proceeded to surgery after the second cycle. All 27 patients underwent surgical procedures. The primary endpoint ORR was 55.6% (15/27), with a tumor control rate of 100%. All patients demonstrated tumor reduction prior to nephrectomy, with an average maximum tumor diameter reduction rate of 26.5%. Furthermore, 100% of patients completed partial nephrectomy. Two patients achieved pathological complete response, and all patients exhibited tumor necrosis, with an average tumor necrosis rate of 45%. Adverse events (AEs) of grade ≥3 occurred in 10.5% of patients, including hyperglycemia and elevated ALT/AST. One patient experienced a grade 4 AE, and no grade 3 postoperative complications were reported. The main limitation of this study is that it is a single-center, small-sample study. Conclusions: Cadonilimab combined with Lenvatinib for neoadjuvant treatment in early clear cell renal carcinoma with indications for partial nephrectomy but high surgical risk demonstrates clear efficacy and safety, warranting further clinical validation. Clinical trial information: NCT06138496 .
Paclitaxel, ifosfamide, cisplatin (TIP) in patients with advanced urethral adenocarcinoma: A single center, retrospective analysis.
656 Background: Urethral adenocarcinoma (UA) is a very rare subtype of cancers arising in urethra, which is known for female predominance and poor prognosis. Rarity of UA impedes the conduction of prospective clinical trial, thus the treatment option for advanced UA is very limited. Usually platinum-based chemotherapy is given based on case reports. We conducted retrospective single center cohort review of TIP regimen in patients (pts) with locally advanced, recurrent or metastatic UA to evaluate its efficacy and safety. Methods: Clinical data of 18 pts with locally advanced, metastatic, or recurrent UA who received TIP regimen at the Department on Oncology, Asan Medical Center from Jul 2016 to Jan 2024 were collected. To be eligible, pts should have histologic confirmation of adenocarcinoma, adequate clinical information, and baseline and follow-up imaging test results. TIP regimen consists of paclitaxel 200 mg/m 2 over 3 hours intravenously (iv) on day 1 (D1), ifosfamide 1,500 mg/m 2 over 1 hour iv on D1-3 with mesna 300 mg/m 2 3 times a day iv on D1-3, and cisplatin 70 mg/m2 over 1 hour iv on D1. We recommended pegylated G-CSF for prevention of severe neutropenia and febrile neutropenia. The primary endpoint was objective response rate (ORR) according to RECIST v1.1, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity. Results: A total of 18 pts were enrolled. All pts were female, and median age was 62 (range 43-74). Disease status was locally advanced (32%), recurrent (47%), and initially metastatic (16%), and ECOG PS were 0 (22%), 1 (72%), and 2 (6%). Most common site of metastasis were lymph nodes (50%), surgical bed (22%), lung (22%), and peritoneum (17%). Patients received TIP as 1 st line (67%) and 2 nd line (33%). Thirteen pts received prophylactic pegylated G-CSF. Median 4 cycles (range 1-6) of TIP were administered, and ORR was 44% (partial response 44%, stable disease 50%, and progressive disease 6%). With a median follow-up duration of 38.7 months, median PFS and OS were 7.0 months [95% confidence interval (CI) 3.8-10.2] and 40.0 months (15.6-63.7), respectively. Most common adverse events included anemia, peripheral neuropathy, anorexia, nausea, fatigue, neutropenia, thrombocytopenia. Most adverse events were manageable, and no unexpected toxicities were found. Conclusions: TIP showed promising efficacy in pts with advanced UA. TIP might be considered as one of treatment options for pts with advanced UA, although efficacy and safety should be validated in larger cohort.
NGS-based molecular panel analysis of metastatic prostate cancer for daily routine: How often do we detect druggable mutations?
203 Background: Guidelines recommend molecular analysis to identify druggable mutations after failure of the first-line systemic therapy for metastatic prostate cancer (mPCA). We report our results of molecular diagnostics in mCRPC patients. Methods: From 2018 to 2023, 311 mCRPC patients underwent molecular panel analysis of archived prostatectomy samples (n=96) or CT-guided biopsies of progressive metastases (n=215) using standardized NGS procedures after the failure of first- or second-line systemic therapy. Mutation analysis was initially performed using NGS with a custom "Prostate Cancer Panel" of 18 multiplex PCR amplicons (AR, ATM, AURKA/MYC, BRCA1/2, CDK12, CTNNB1, DLL3, ETS family, FOXA1, FOXO1, MED12, PIK3CA, PTEN, RAD51C, TP53, Wnt-Pathway), generated using a GeneRead DNAseq Custom Panel V2 (Qiagen). Since 2023, we perform apply the TSO500 panel in selected cases. Analysis of HRD was performed by combining BRCA1 and BRCA2 mutations with the HRD score (Genomic ScarScore GSS) using the HANDLE HRD Focus Panel (Halo-shape Annealing and Defer-Ligation Enrichment, AmoyDx). The data were evaluated using the following thresholds: tumor cell content ≥ 30%, GScore positive at ≥ 50, HRD positive: GScore at ≥ 50 or BRCA1/2 category 4/5 mutation. In addition MSI-high and mutations of MSH2, MSH6, PMS2, and MLH1 were analysed. The following databases were reviewed to identify druggable mutations: OncoKB, ClinVar, JAX-CKB, COSMIC, and My Cancer Genome. Results: Out of 311 biopsies, 299 (96%) had sufficient DNA content for NGS. NGS was performed from prostate (31%), lymph node (30%), visceral (15%), and bone (24%) metastases with informative DNA retrival in 95%, 95%, 92%, and 85%, respectively. Overall, 157 patients (50.5%) had no or non druggable mutations, while 154 patients (49.5%) exhibited druggable mutations. HRD gene mutations (BRCA1/2, ATM, CDK12, CHEK2, FANCA, Rad51C) and inactivating p53 mutations were observed in 66 patients (22%). 3 patients had p53 mutations with gain-of-function resulting in ATM inactivation. 50% HRD gene mutations including a positive HRD score were pathogen and treated with PARPi resulting in a progression-free survival of 3-28 months. Activating androgen receptor mutations and inactivating PTEN/activating PIK3Ca mutations were found in 42 (14%) and 24 (8%) patients, resp. Switch of treatment for AR mutation resulted in PFS of 6-9 months. Mismatch repair deficiency/MSI high mutations were identified in 3 cases who received pembrolizumab with a PFS of 4-8 months. Conclusions: NGS analysis in mCRPC reveals mutations in two-thirds of patients, of which 41% are already druggable. Only 50% of druggable mutations are based on BRCA1/2 or ATM. NGS analysis should be integrated into the diagnostic armamentarium following failure of first-line systemic therapy for mCRPC.
Enzymatic conversion of blood group B kidney prevents hyperacute antibody-mediated injuries in ABO-incompatible transplantation
Machine learning prediction of glaucoma by heavy metal exposure: results from the National Health and Nutrition Examination Survey 2005 to 2008
Site-specific disease progression in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab or axitinib-based immunotargeted combinations.
478 Background: Data on site-specific progression patterns in metastatic renal cell carcinoma (mRCC) treated with immuno-oncology agents are limited. This study aimed to characterize sites of progression in patients receiving nivolumab plus ipilimumab (Nivo-Ipi) or axitinib-based immunotargeted combinations in the first-line setting. Methods: A retrospective, observational cohort study included patients with clear-cell mRCC who received either Nivo-Ipi (Cohort A) or pembrolizumab-axitinib and avelumab-axitinib (Cohort B) from 2018 to 2024. The primary objective was to assess the occurrence of new lesions in different organs. Secondary analysis evaluated disease progression by an increase of more than 20% in target lesion size. Results: A total of 334 patients were identified, with radiographic progression observed in 86.3% (107/124) of Cohort A and 60% (126/210) of Cohort B. In the ITT population (n=233), the median age at mRCC diagnosis was 59.7 years (range 31–84), 79% were male, 74% had undergone nephrectomy, 61% had intermediate IMDC risk, and 64% had two or more metastatic sites. Cohort B had a younger median age (60.2 vs. 65.4 years), a higher incidence of bone metastases (28.6% vs. 13.1%), and more favorable risk (15.1% vs. 0.9%) compared to Cohort A. The site-specific rate of new lesions differed between cohorts (Table). Progression due to increased target lesions occurred in 60.7% (65/107) of Cohort A and 77.8% (98/126) of Cohort B patients. Conclusions: New lesion development was more frequent with Nivo-Ipi, with lymph nodes being the most common site of new lesions of mRCC across both cohorts. Cohort An=107 Cohort Bn=126 Baseline At the time of progression Baseline At the time of progression Patients with new lesions, n (%) - 42 (39.3) - 28 (22.2) Sites of metastases, n (%) Lung 73 (68) 81 (76) 76 (60) 79 (63) Lymph node 55 (51) 94 (88) 68 (54) 81 (64) Liver 27 (25) 28 (26) 39 (31) 47 (37) Bone 14 (13) 26 (24) 36 (29) 41 (33) Adrenal gland 19 (18) 20 (19) 20 (16) 28 (22) Contralateral kidney 5 (5) 5 (5) 1 (0.8) 2 (1.6) Brain 1 (1) 2 (2) 4 (3) 4 (3) Soft tissues 4 (4) 4 (4) 1 (0.8) 1 (0.8) Pancreas 2 (2) 3 (3) 0 (0) 2 (1.6) Other* 5 (5) 7 (7) 9 (7) 9 (7) *Thyroid gland, pleura, peritoneum, ovary, breast.
Optyx study: Clinical characteristics and preferences for initiating relugolix in a cohort of US patients in real-world care settings.
67 Background: Relugolix is the only oral androgen deprivation therapy indicated for advanced prostate cancer (PC). The OPTYX study is the first prospective study to collect evidence on the long-term safety, effectiveness, treatment patterns, disease course, and patient outcomes with relugolix in real-world care. Enrollment is completed and this analysis assessed key baseline variables, reasons for starting relugolix, and treatment patterns. Methods: The multi-center observational OPTYX study enrolled men with PC starting relugolix across various disease stages and treatment regimens (e.g., mono or combination therapy). Enrollment occurred in diverse clinical settings including urology, oncology, and radiation oncology. Eligibility required intent to treat with relugolix for more than 4 months. Data collected included baseline demographics, clinical characteristics, reasons for initiating treatment, treatment patterns, and quality of life (FACT-P) questionnaires from Oct 2022 to Sept 2024. Results: By September 2024, 999 men were enrolled and received relugolix with a median treatment duration of 242 days. The median age was 71 years; 77.4% self-identified as White, 16.4% as Black. Over 80% submitted FACT-P questionnaires at baseline. Disease states included localized (42.0%), locally advanced (16.7%), biochemical recurrence (11.2%), metastatic castration sensitive PC (18.7%), non-metastatic (1.5%), metastatic castration resistant PC (4.8%), and unknown (5.0%). Of these, 476 men (47.7%) received relugolix in combination with other PC therapies including radiation and systemic therapies. Prior ADT was reported in 21.0% of patients. Mean (SD) baseline testosterone and PSA were 293.1 (227.8) ng/dL and 61.3 (342.4) ng/mL, respectively. The top reasons physicians prescribed relugolix were preference for oral over injection administration (41.5%), rapid testosterone suppression (34.6%), and safety (29.0%), while patients reported physician recommendation (72.3%), oral over injection (36.4%), and rapid testosterone recovery (10.2%). Conclusions: The OPTYX study enrolled 999 patients to assess real-world experience with relugolix. Nearly half started relugolix with other therapies. Many patients and physicians preferred the oral formulation, and other top reasons for initiation included safety and rapid testosterone suppression and recovery. Clinical trial information: NCT05467176 . Relugolix Initiation Preference n (%) By Physician By Patient Oral Instead of Injection 415 (41.5) 364 (36.4) Rapid Testosterone Suppression 346 (34.6) 98 (9.8) Safety Profile 290 (29.0) 95 (9.5) Efficacy Data 255 (25.5) 66 (6.6) Rapid Testosterone Recovery 209 (20.9) 102 (10.2) Tolerability 119 (11.9) 55 (5.5) Co-morbid Disease 76 (7.6) 17 (1.7) Physician Recommended 60 (6.0) 722 (72.3) Other/Unknown 45 (4.5) 22 (2.2)
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq.
713 Background: The combination of antibody-drug conjugates (ADCs) and immunotherapy has great prospects for first-line treatment of advanced urothelial carcinoma (UC). This study aimed to explore the efficacy, safety, and prognostic biomarkers of disitamab vedotin (DV) combined with a PD-1 inhibitor and compared them with other first-line regimens without DV. Methods: Patients with advanced UC received first-line treatment and were enrolled retrospectively from July 2021 to December 2023 in two cancer centers. Propensity score (PS) matching analysis was used to compare the DV group and the non-DV group. In the DV group, RNA-seq was used to analyze differential expressed genes. Results: A total of 97 patients were included. The 1-year overall survival (OS) and progression-free survival (PFS) rates were 74.4% and 49.7%, respectively. PS score and first-line treatment regimen were independent prognostic factors for both OS and PFS. Survival analysis showed that DV combined with PD-1 inhibitor significantly improved PFS compared with other 3 regimens, including chemotherapy alone (P≤0.01), PD-1 inhibitor plus chemotherapy (P≤0.01), and PD-1 inhibitor alone (P≤0.01). DV combined with PD-1 inhibitor also led to better OS compared to chemotherapy (P≤0.01) or PD-1 inhibitor alone(P≤0.01), with a trend toward improved OS versus PD-1 inhibitor plus chemotherapy (P=0.129). After PS matching, there were 40 patients, each in the DV group and Non-DV group. There were significant differences between the DV group and Non-DV group in terms of objective response rate (77.5% vs.37.5%, p=0.001), 1-year PFS rate (72% vs.22.2%, p=0.000), and 1-year OS rate (84% vs. 62%, p=0.003). Additionally, differentially expressed genes were identified between patients using DV with PFS >1 year and PFS <1 year and RNA-Seq analysis highlighted enriched pathways such as cytosolic and metabolic pathways, offering potential insights into DV resistance mechanisms. Conclusions: The first-line regimen of DV plus immunotherapy for patients with advanced UC was more effective and safer than the regimen without DV.
Evaluating survival in aggressive variant prostate cancer patients undergoing PSMA radioligand therapy.
259 Background: Aggressive variant prostate cancer (AVPC) is a subtype of metastatic castrate-resistant prostate cancer (mCRPC) characterized by several high-risk features. AVPC is associated with poorer overall survival and has limited response to androgen receptor targeted therapy, although it often shows some responsiveness to chemotherapy. In this study, we evaluated the outcomes of AVPC patients who received Prostate-Specific Membrane Antigen (PSMA) radioligand therapy (RLT). Methods: This retrospective study included 201 mCRPC patients who received Lutetium-177, [ 177 Lu]-PSMA RLT at two academic centers. Patients were classified as having AVPC based on the presence of at least one of the following eight criteria: exclusive visceral metastases (n=1), predominantly lytic bone metastasis (n=1), bulky lymphadenopathy or pelvic mass (≥5 cm) (n=4), low PSA (≤10 ng/mL) at initial presentation plus high-volume (≥20) bone metastases (n=0), serum CEA and/or LDH levels twice the upper limit of normal at the time of treatment (n=5), a short interval (≤6 months) to CRPC (n=7), small cell/neuroendocrine carcinoma morphology (n=5), and the presence of two or more genomic defects among TP53, RB1, and PTEN (n=13). Results: Of the 201 patients, 34 (16.9%) were classified as having AVPC (Table). The PSA50 response rate was 55% in the AVPC group and 60% in the non-AVPC group. The median overall survival (OS) (median time from the start of therapy to the last follow-up or death) was 171 days for the AVPC group and 282 days for the non-AVPC group. Although, the Kaplan-Meier plot only suggested a trend toward worse survival in AVPC patients compared to non-AVPC patients, the difference did not reach statistical significance (log-rank test p-value = 0.179). Conclusions: Our study suggests patients with AVPC may benefit from PSMA RLT and should be considered for this treatment if they are eligibly. Further studies are needed for a better understanding of this patient population. Details of patients. AVPC Non AVPC N=201 34 167 Age 1 (mean, year) 64.38 64.09 PSA 2 (mean, ng/mL) 331 251 PSA 3 (mean, ng/mL) 717 504 PSA50 (%) 55 60 OS/FU (median, day) 171 282 1 Age at the time of therapy. 2 Baseline PSA at diagnosis. 3 Most recent PSA prior to therapy.